607 related articles for article (PubMed ID: 34388530)
1. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
[TBL] [Abstract][Full Text] [Related]
2. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
[TBL] [Abstract][Full Text] [Related]
3. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
4. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
5. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
[TBL] [Abstract][Full Text] [Related]
6. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
7. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
8. Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
Istifli ES; Netz PA; Sihoglu Tepe A; Sarikurkcu C; Tepe B
J Biomol Struct Dyn; 2022; 40(23):12760-12771. PubMed ID: 34495817
[TBL] [Abstract][Full Text] [Related]
9. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Chatterjee D; Tauzin A; Laumaea A; Gong SY; Bo Y; Guilbault A; Goyette G; Bourassa C; Gendron-Lepage G; Medjahed H; Richard J; Moreira S; Côté M; Finzi A
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062348
[TBL] [Abstract][Full Text] [Related]
11. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
12. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
Sinha S; Tam B; Wang SM
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
[TBL] [Abstract][Full Text] [Related]
13. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
14. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P
Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558
[TBL] [Abstract][Full Text] [Related]
15. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.
Wu CY; Lin YS; Yang YH; Shu LH; Cheng YC; Liu HT
Front Pharmacol; 2020; 11():584158. PubMed ID: 33390952
[TBL] [Abstract][Full Text] [Related]
16. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
Wang R; Chen J; Gao K; Wei GW
Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
[TBL] [Abstract][Full Text] [Related]
18. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
19. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
